Novartis reaffirms $12 billion Avidity acquisition despite $1.9 billion impairment loss

Novartis said its $12 billion purchase of Avidity Biosciences remains on track, according to CEO Vas Narasimhan.

The comment followed the company's disclosure of a $1.9 billion impairment charge tied to a late‑stage neuromuscular disease asset that failed to meet expectations.

Narasimhan emphasized confidence in Avidity’s platform and the strategic value of the deal, suggesting the setback does not alter the long‑term growth plan.

Analysts will watch how the write‑down impacts Novartis’s financial outlook while the acquisition proceeds as planned.